Risankizumab is a humanized monoclonal antibody that targets interleukin (IL-)23, approved for the treatment of moderate-to-severe plaque psoriasis, which has shown efficacy in both clinical trials and real-world experiences.1–4 However, there is still limited knowledge regarding which patients could benefit the most from the therapy with risankizumab
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Damiani G;Girolomoni G;Lasagni C;Maurelli M;Orsini D;
2024-01-01
Abstract
Risankizumab is a humanized monoclonal antibody that targets interleukin (IL-)23, approved for the treatment of moderate-to-severe plaque psoriasis, which has shown efficacy in both clinical trials and real-world experiences.1–4 However, there is still limited knowledge regarding which patients could benefit the most from the therapy with risankizumab
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Gargiulo RIS JEADV 2024.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
2.01 MB
Formato
Adobe PDF
|
2.01 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
